---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026346"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:20:03.431878+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics raises ~$7.9M in private placement of common stock and warrants

## Summary
- Gross proceeds ~$7.9M from sale of ~7.36M shares and warrants at $1.08 per unit.
- Warrants exercisable after 6 months at $1.08/share, expire in 5 years.
- Proceeds to advance C. diff and type 1 diabetes pipeline and for working capital.
- Existing investors including T. Denny Sanford and new institutional investors participated.
- Brookline Capital Markets acted as exclusive placement agent.

## SEC filing metadata
- accession: 0000950170-22-026346
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/0000950170-22-026346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/sabs-20221206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026346
- JSON: https://secwatch.observer/filing/0000950170-22-026346.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026346.txt

## Key facts
- Material Agreements
  SAB Biotherapeutics, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $8.0 million (effective 2022-12-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $8.0 million
  - Effective: 2022-12-06
  source text: On December 6, 2022, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/0000950170-22-026346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.